Tasuku Nakabori

Chuo, 5418567, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Correction: Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: A Single-Center Retrospective Study.

Correction: Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: A Single-Center Retrospective Study.

Journal: Journal of gastrointestinal cancer

Published: August 15, 2026

Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.

Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.

Journal: Cancers

Published: April 18, 2026

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Journal for immunotherapy of cancer

Published: March 16, 2026

Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.

Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.

Journal: Journal for immunotherapy of cancer

Published: March 16, 2026

Long-anchoring Stent Method as a Rescue Technique for Early Dysfunction of Covered Self-Expandable Metal Stents in Distal Malignant Biliary Obstruction: A Retrospective Case Series.

Long-anchoring Stent Method as a Rescue Technique for Early Dysfunction of Covered Self-Expandable Metal Stents in Distal Malignant Biliary Obstruction: A Retrospective Case Series.

Journal: DEN open

Published: March 14, 2026

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Journal: PloS one

Published: January 29, 2026

Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: a Single-Center Retrospective Study.

Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: a Single-Center Retrospective Study.

Journal: Journal of gastrointestinal cancer

Published: December 31, 2025

Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma.

Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma.

Journal: International journal of clinical oncology

Published: December 29, 2025

Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer.

Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer.

Journal: Journal of gastrointestinal cancer

Published: August 27, 2025

NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.

NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: August 21, 2025

Advancing Gene Mutation Analysis Through Post-Ablation Liver Tumor Biopsy Specimens.

Advancing Gene Mutation Analysis Through Post-Ablation Liver Tumor Biopsy Specimens.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 25, 2025

Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment.

Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment.

Journal: Cancer reports (Hoboken, N.J.)

Published: May 18, 2025

Showing 1-12 of 68

Last Updated: 09/26/2026